<DOC>
	<DOCNO>NCT01690845</DOCNO>
	<brief_summary>Hypoxic hepatitis ( HH ) report frequent cause elevate aminotransferase level hospital . Up 10 % critically ill patient develop HH course intensive care unit ( ICU ) stay . Occurrence HH life threaten event ICU-mortality report 60 % . Early therapeutic intervention central prognostic importance patient HH improve hemodynamic impairment early possible , reduce hyperammonemia hepatic encephalopathy , avoid progression organ failure improve outcome . Studies report Molecular Adsorbent Recirculating System ( MARS® ) therapy improve hemodynamic situation patient acute acute chronic liver failure . The study hypothesis MARS® therapy critically ill patient severe HH improve hepatic hemodynamics function consecutively course disease . 40 patient suffer severe HH aminotransferase level &gt; 40 time upper limit normal 12 hour randomize 1:1 MARS® therapy ( n=20 ) conventional therapy ( n=20 ) . 4 MARS®-sessions perform three consecutive day , least 12 hour . Treatment continue special circumstance . The maximum duration treatment phase 7 day . The primary endpoint difference indocyanine plasma disappearance rate day 7 . The expected duration study 2 year .</brief_summary>
	<brief_title>Molecular Adsorbent Recirculating System ( MARS® ) Hypoxic Hepatitis</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>Anoxia</mesh_term>
	<mesh_term>Liver Failure , Acute</mesh_term>
	<criteria>presence severe hypoxic hepatitis aminotransferase level &gt; 40 time upper limit normal duration hypoxic hepatitis 12 hour age &gt; /= 18 year age &lt; 18 year pregnancy DNR order liver cirrhosis Cardiopulmonary resuscitation unknown neurological outcome and/or hypoxic brain damage Expected survival less 24 hour</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>